These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 24040994)
1. Evaluation of the carcinogenicity of inorganic arsenic. Cohen SM; Arnold LL; Beck BD; Lewis AS; Eldan M Crit Rev Toxicol; 2013 Oct; 43(9):711-52. PubMed ID: 24040994 [TBL] [Abstract][Full Text] [Related]
2. Research toward the development of a biologically based dose response assessment for inorganic arsenic carcinogenicity: a progress report. Clewell HJ; Thomas RS; Gentry PR; Crump KS; Kenyon EM; El-Masri HA; Yager JW Toxicol Appl Pharmacol; 2007 Aug; 222(3):388-98. PubMed ID: 17499324 [TBL] [Abstract][Full Text] [Related]
3. Quantitative assessment of lung and bladder cancer risk and oral exposure to inorganic arsenic: Meta-regression analyses of epidemiological data. Lynch HN; Zu K; Kennedy EM; Lam T; Liu X; Pizzurro DM; Loftus CT; Rhomberg LR Environ Int; 2017 Sep; 106():178-206. PubMed ID: 28625818 [TBL] [Abstract][Full Text] [Related]
4. Arsenic-induced bladder cancer in an animal model. Cohen SM; Ohnishi T; Arnold LL; Le XC Toxicol Appl Pharmacol; 2007 Aug; 222(3):258-63. PubMed ID: 17109909 [TBL] [Abstract][Full Text] [Related]
5. Use of mode of action data to inform a dose-response assessment for bladder cancer following exposure to inorganic arsenic. Gentry PR; Yager JW; Clewell RA; Clewell HJ Toxicol In Vitro; 2014 Oct; 28(7):1196-205. PubMed ID: 24937311 [TBL] [Abstract][Full Text] [Related]
6. Arsenic exposure and bladder cancer: quantitative assessment of studies in human populations to detect risks at low doses. Tsuji JS; Alexander DD; Perez V; Mink PJ Toxicology; 2014 Mar; 317():17-30. PubMed ID: 24462659 [TBL] [Abstract][Full Text] [Related]
7. Arsenic-induced carcinogenesis--oxidative stress as a possible mode of action and future research needs for more biologically based risk assessment. Kitchin KT; Conolly R Chem Res Toxicol; 2010 Feb; 23(2):327-35. PubMed ID: 20035570 [TBL] [Abstract][Full Text] [Related]
8. Dose-response for assessing the cancer risk of inorganic arsenic in drinking water: the scientific basis for use of a threshold approach. Tsuji JS; Chang ET; Gentry PR; Clewell HJ; Boffetta P; Cohen SM Crit Rev Toxicol; 2019 Jan; 49(1):36-84. PubMed ID: 30932726 [TBL] [Abstract][Full Text] [Related]
9. Comparative toxicity of arsenic metabolites in human bladder cancer EJ-1 cells. Naranmandura H; Carew MW; Xu S; Lee J; Leslie EM; Weinfeld M; Le XC Chem Res Toxicol; 2011 Sep; 24(9):1586-96. PubMed ID: 21815631 [TBL] [Abstract][Full Text] [Related]
10. Diuron-induced rat urinary bladder carcinogenesis: mode of action and human relevance evaluations using the International Programme on Chemical Safety framework. Da Rocha MS; Arnold LL; De Oliveira ML; Catalano SM; Cardoso AP; Pontes MG; Ferrucio B; Dodmane PR; Cohen SM; De Camargo JL Crit Rev Toxicol; 2014 May; 44(5):393-406. PubMed ID: 24512549 [TBL] [Abstract][Full Text] [Related]
11. Dietary administration of sodium arsenite to rats: relations between dose and urinary concentrations of methylated and thio-metabolites and effects on the rat urinary bladder epithelium. Suzuki S; Arnold LL; Pennington KL; Chen B; Naranmandura H; Le XC; Cohen SM Toxicol Appl Pharmacol; 2010 Apr; 244(2):99-105. PubMed ID: 20045014 [TBL] [Abstract][Full Text] [Related]
12. Low-level arsenic exposure in drinking water and bladder cancer: a review and meta-analysis. Mink PJ; Alexander DD; Barraj LM; Kelsh MA; Tsuji JS Regul Toxicol Pharmacol; 2008 Dec; 52(3):299-310. PubMed ID: 18783726 [TBL] [Abstract][Full Text] [Related]
13. Evidence for toxicity differences between inorganic arsenite and thioarsenicals in human bladder cancer cells. Naranmandura H; Ogra Y; Iwata K; Lee J; Suzuki KT; Weinfeld M; Le XC Toxicol Appl Pharmacol; 2009 Jul; 238(2):133-40. PubMed ID: 19442679 [TBL] [Abstract][Full Text] [Related]
14. Inorganic arsenic: A non-genotoxic carcinogen. Cohen SM; Chowdhury A; Arnold LL J Environ Sci (China); 2016 Nov; 49():28-37. PubMed ID: 28007178 [TBL] [Abstract][Full Text] [Related]
15. Carcinogen exposure and epigenetic silencing in bladder cancer. Marsit CJ; Karagas MR; Schned A; Kelsey KT Ann N Y Acad Sci; 2006 Sep; 1076():810-21. PubMed ID: 17119258 [TBL] [Abstract][Full Text] [Related]
16. Bayesian benchmark dose analysis for inorganic arsenic in drinking water associated with bladder and lung cancer using epidemiological data. Shao K; Zhou Z; Xun P; Cohen SM Toxicology; 2021 May; 455():152752. PubMed ID: 33741492 [TBL] [Abstract][Full Text] [Related]
17. Characterization of intracellular inclusions in the urothelium of mice exposed to inorganic arsenic. Dodmane PR; Arnold LL; Muirhead DE; Suzuki S; Yokohira M; Pennington KL; Dave BJ; Lu X; Le XC; Cohen SM Toxicol Sci; 2014 Jan; 137(1):36-46. PubMed ID: 24097667 [TBL] [Abstract][Full Text] [Related]
18. Physiologically based pharmacokinetic modeling of arsenic in the mouse. Gentry PR; Covington TR; Mann S; Shipp AM; Yager JW; Clewell HJ J Toxicol Environ Health A; 2004 Jan; 67(1):43-71. PubMed ID: 14668111 [TBL] [Abstract][Full Text] [Related]
19. Mechanisms of action for arsenic in cardiovascular toxicity and implications for risk assessment. Sidhu MS; Desai KP; Lynch HN; Rhomberg LR; Beck BD; Venditti FJ Toxicology; 2015 May; 331():78-99. PubMed ID: 25771173 [TBL] [Abstract][Full Text] [Related]
20. Inorganic arsenic-induced intramitochondrial granules in mouse urothelium. Suzuki S; Arnold LL; Muirhead D; Lu X; Le XC; Bjork JA; Wallace KB; Ohnishi T; Kakiuchi-Kiyota S; Pennington KL; Cohen SM Toxicol Pathol; 2008 Dec; 36(7):999-1005. PubMed ID: 19126794 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]